(Information sent by the signatory company)

ALPHARETTA, Ga. , May 1, 2024/PRNewswire/ — MagVenture is proud to announce its partnership with Magnus Medical, providing its industry-leading MagPro® magnetic stimulation system to support an exciting new chapter in therapeutic transcranial magnetic stimulation (TMS). through Magnus’ SAINT® neuromodulation system. SAINT therapy will allow patients to receive rapid and highly effective treatment for major depressive disorder (MDD), especially in acute situations where the adoption of TMS has been limited.

SAINT therapy is a non-invasive, fast-acting, FDA-approved treatment for treatment-resistant major depression in adults who have not achieved satisfactory improvement with prior antidepressant medications. The treatment consists of MRI-guided stimulation target identification and a proprietary protocol that condenses the treatment into just five days.

“MagVenture’s high-performance intermittent theta burst system underpins our innovative SAINT therapy, so we are poised to deliver fast, effective relief to people suffering from treatment-resistant depression,” said Christian Gormsen, President and CEO. by Magnus Medical. “This collaboration underscores our commitment to advancing the treatment of neuropsychiatric disorders and changing people’s lives.”

Kerry Rome, Senior Vice President of Sales and Marketing at MagVenture, Inc. continued: “We are excited to enable SAINT’s expansion into the United States with MagVenture hardware, as well as installation and service support to ensure customers offering SAINT experience the same reliable, high-quality operations that MagVenture is known for.”

MagVenture and Magnus Medical will be exhibiting at the upcoming Clinical TMS Society annual meeting in London in June, where you can see the SAINT system first-hand.

About MagVenture

MagVenture is a market-leading privately held manufacturer of non-invasive TMS systems worldwide. Based in Denmark, MagVenture has been a pioneer in cutting-edge TMS solutions for over 30 years. MagVenture systems are used for both research and treatment in the fields of psychiatry, neurophysiology, neurology, cognitive neuroscience, and rehabilitation. For more information, visit www.magventure.com

Media inquiries:

Kerry Rome kr@magventure.com o Lauren Schultheiss ls@magventure.com, MagVenture, Inc., 1.888.624.7764

Logo – https://mma.prnewswire.com/media/2402306/Logo_2700_px_wide_Logo.jpg

View original content: https://www.prnewswire.com/news-releases/magventure-se-asocia-con-magnus-medical-para-llevar-al-mercado-el-sistema-de-neuromodulacion-saint-302133016.html